Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Pacira Pharmaceuticals

Share:
Related PCRX
Leerink Swann Initiates Pacira Pharmaceuticals With Market Perform
Benzinga's Top Initiations
Should You Get Rid of Pacira Pharmaceuticals (PCRX) Now? - Tale of the Tape (Zacks)

In a report published Friday, Jefferies & Company reiterated its Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX), and raised its price target from $22.00 to $24.00.

Jefferies noted, “PCRX completed a strong round of financing ($110M ‘convert' at favorable terms) removing a financing overhang – we had modeled cash needs in '13 – and provides a clear runway to profitability in '14. Q4 pre-announced Exparel sales beat estimates and the Exparel commercial metrics bode very well and support our bullish sales estimates. We raise our PT to $24 based on Exparel trends and removal of financing risk.”

Pacira Pharmaceuticals closed on Thursday at $19.43.

Latest Ratings for PCRX

DateFirmActionFromTo
Jun 2015Leerink SwannInitiates Coverage onMarket Perform
May 2015Canaccord GenuityMaintainsBuy
Mar 2015BarclaysMaintainsOverweight

View More Analyst Ratings for PCRX
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (PCRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters